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ABSTRACT 
 
Effects of Simvastatin and Fluvastatin on Endothelial Invasion. (April 2009) 
 
Evan Michael Cherry 
Department of Chemical Engineering 
Texas A&M University 
 
Research Advisor: Dr. Kayla Bayless 
Department of Molecular & Cellular Medicine 
 
Endothelial invasion is a crucial step in angiogenic blood vessel formation and has 
ramifications in wound healing, tumor growth, and may have implications in heart 
disease. During invasion, quiescent endothelial cells (ECs) proteolyze their basement 
membrane, proliferate, and sprout into the extracellular matrix. This process is partially 
mediated by contact feedback from integrins and stimulated by angiogenic growth 
factors Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor 
(bFGF), as well as the lysosphingolipid Sphingosine-1-Phosphate (S1P). Invasion is 
distinguishable by dramatic EC morphological changes from simple squamous cells to 
sprouting structures that ultimately form new lumens.  
  
Cholesterol synthesis is inhibited by a class of drugs called HMG-CoA Reductase 
inhibitors, also known as statins. Statins are the first line of pharmacological treatment 
for reducing cholesterol levels when diet and lifestyle changes are not sufficient. 3-
hydroxy-3-methylglutaryl-CoenzymeA (HMG-CoA) Reductase is the key rate-
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determining enzyme of the mevalonate pathway, the biological process by which 
dimethylallyl pyrophosphate and isopentyl pyrophosphate (sterol precursors) are 
synthesized. Statins are effective in reducing the risk of atherosclerosis, a major cause of 
cardiovascular disease and studies have shown that statins may have secondary 
protective effects.  
  
In our study, we tested the effects of statins on endothelial cell invasion. To investigate 
the effects of statins on endothelial function, we studied the effects of two different 
statins on regulating endothelial invasion of three-dimensional collagen matrices. The 
natural product-derived Simvastatin (ZOCOR®) and the synthetic Fluvastatin 
(LESCOL®) both lowered cellular cholesterol levels and inhibited invasion. Both were 
tested at concentrations within the range of human plasma levels and in the presence of 
S1P, VEGF, and FGF. Differences in the known signaling proteins Erk 1/2, Akt, and 
Paxillin were analyzed by gel electrophoresis and western blotting.  
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NOMENCLATURE 
 
BSA  Bovine Serum Albumin 
DAPI  4',6-Diamidino-2-Phenylindole 
EC Endothelial Cell 
ECL  Enhanced Chemiluminescence 
FBS  Fetal Bovine Serum 
G3PDH  Glyceraldehyde-3-Phosphate Dehydrogenase 
GF Growth Factor 
SB Sample Buffer 
HDL High-Density Lipoprotein 
HMG CoA Reductase 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase 
HRP  Horseradish Peroxidase 
LDL Low-Density Lipoprotein 
ME  2-Mercapto-Ethanol 
P- Phospho- 
PBS Phosphate Buffered Saline 
PVDF  Polyvinylidene difluoride 
S1P Sphingosine-1-Phosphate 
SDS-PAGE Sodium Dodecyl Sulfate Poly-Acrylamide Gel 
Electrophoresis 
Statin HMG-CoA Reductase Inhibitor 
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CHAPTER I 
INTRODUCTION 
 
Atherosclerosis and statins 
Cholesterol regulation has become one of the primary methods for preventing heart 
disease.  HMG-CoA Reductase inhibitors (statins), the first line of treatment for 
inhibiting cholesterol synthesis, lowering blood cholesterol levels and significantly 
reduce both atherosclerosis [1] and the instance of heart disease by 60%. [2]  
 
 Atherosclerosis is the buildup of fatty plaques along the interior lining of blood vessels. 
Various stress factors oxidize the cholesterol transport molecule Low density 
Lipoproteins (LDL). Oxidized LDL adheres to the lining of blood vessels and 
encourages foam cell accumulation and plaque growth which reduces blood flow and 
can lead to a heart attack. [3] Plaque rupture can result in a stroke.  The Agency for 
Healthcare Research and Quality found that in 2005, 29.7 million people purchased 
statins for an estimated total of 19.7 billion dollars. [4] The structures of the two statins 
used in this project are shown in (Fig. 1) and their plasma levels after initial dose are 
shown in (Fig. 2). [5-6] 
_______________ 
This thesis follows the style of Biochemical and Biophysical Research Communications. 
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Physiological 
levels: 
120ng/ml (300nM) 
Physiological 
levels: 
5ng/ml (12nM)  
 
 
 
  
Fig.1. Structures of (A) Simvastatin and (B) Fluvastatin. Simvastatin is derived from 
lovastatin, a naturally-occurring compound in the fungus Aspergillus terreus. 
Fluvastatin, a synthetic statin, has a visibly different structure. 
 
 
 
 
Fig 2. Plasma concentrations of (A) Simvastatin, and (B) Fluvastatin. Simvastatin 
reaches a peak of approximately 12 nM within the first two hours. Fluvastatin levels in 
plasma peak at approximately 300 nM within the first hour. 
 
 
 
A 
A B 
B 
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Angiogenesis 
Patients treated with statins exhibit other cardiovascular protective effects, including a 
lower incidence of cancer. [7-8] New blood vessel growth, or angiogenesis, is required 
for tumor growth and wound healing. These data have helped form the basis for our 
hypothesis that statins may affect angiogenesis. 
 
During angiogenesis, endothelial cells lining blood vessels respond to extracellular 
signals and change into invading structures (Fig. 3). In wound healing, the process relies 
on platelets, fibroblasts, and neighboring endothelial cells. The endothelial cells entering 
the surrounding matrix initiate new blood vessel growth. Endothelial cells propagate 
across the gap until they make contact other endothelial cells, cease multiplying, and 
migrate into the extracellular matrix in response to a sphingosine-1-phosphate (S1P) and 
angiogenic growth factor gradient. [9] The simultaneous combination of lipid inducers, 
contact feedback, and growth factors is required for endothelial invasion. [10-11] 
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Fig 3. Summary of Angiogenesis. Endothelial cells lining blood vessels degrade the 
basement membrane and invade into the extracellular matrix in response to lipid and 
growth factor gradients. 
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CHAPTER II 
METHODS 
 
Reagents 
D-Erythro-Sphingosine-1-Phosphate (S1P) was purchased from Avanti Polar Lipids. 
Simvastatin sodium salt and fluvastatin sodium salt were purchased from Calbiochem. 
Simvastatin sodium salt was reconstituted in DMSO and fluvastatin sodium salt was 
reconstituted in sterile water. Fetal Bovine Serum was obtained from Invitrogen.  All 
other reagents were from Sigma-Aldrich unless otherwise stated.  
 
Collagen extraction 
Rat tail collagen type I was isolated by soaking frozen rat tails in ethanol, removing the 
epidermis from the rat tails, extracting tendons, and removing any muscle or fatty tissue. 
Tendons were then soaked in 150 ml of sterile 0.1% acetic acid and gently shaken for 48 
h. Every 24 h the solution was centrifuged and 40 ml extracts were removed from the 
supernatant and added to separate tubes. Extracts were combined in a lyophylizer bottle 
and rotated while shell-freezing in dry ice until all liquid was frozen. Frozen solution 
was lyophilized until dry product was white and fibrous. Dry collagen product was 
weighed and dissolved in 0.1% acetic acid to a final solution of 7.1 mg collagen/ml.  
 
 
 
  6 
Cell culture 
Human umbilical vein endothelial cells (HUVECs) (Clonetics) were used between 
passages 2 and 6 and grown in 15 ml of Supermedia [Medium 199 (M199) containing 
15% FBS, 0.1mg/ml Heparin, 0.4 mg/ml ECGM from bovine hypothalamus (Pel-Freeze 
Biologicals), 0.01 mg/ml Gentamicin Reagent Solution (Invitrogen), and 1X Antibiotic-
Antimycotic (Invitrogen)] in 75 cm2 flasks (Corning Incorporated). During collection, 
cells were washed twice with HEPES-buffered saline, removed with trypsin-EDTA and 
neutralized with FBS. Cells were washed with M199 to remove serum, centrifuged, re-
suspended in M199, and counted using a hemocytometer. After calculating final dilution 
volume, the cells were centrifuged and re-suspended in equilibrated M199 (37°C and 5% 
CO2) to 4x104 cells/50μl.  
 
Vertical collagen invasion assay 
Collagen matrices were prepared by combining 350 μl of collagen type I solution, 39 μl 
10X M199, 2.1 μl 5N NaOH, and 609 μl M199 on ice and mixing thoroughly after 
adding each component. S1P was added at a final concentration of 1 μM. 28 μl of gel 
was added to wells in a 96-well plate (Corning Inc.) and allowed to polymerize and 
equilibrate at 37°C and 5%CO2. HUVECs (40,000 cells/50 μl) were treated with statin at 
a physiological dose (160 nM fluvastatin or 10 nM simvastatin) (Fig 3) or nothing in a 
test tube for 20 min prior to being added to the wells and allowed to adhere. After 
seeding the cells, each well was given 50 μl of equilibrated media containing reduced-
serum II supplement (Transferrin, BSA, oleic acid, and insulin), 40 ng/ml bFGF and 
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VEGF (Upstate Bio-technology), 50 μg/ml ascorbic acid, and the concentration of statin 
for pretreatment. Cultures were allowed to develop for 24 h before being fixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS) and stained with a 1:10000 
dilution of DAPI in PBS, then counted via UV fluorescence using an eyepiece with an 
ocular grid. A field at the center of each well was selected and counted manually at 10x 
magnification using an Olympus CK3 Microscope. Data is presented as invading cells 
per field (±SD).  
 
Cholesterol quantification 
Cholesterol quantification was conducted using a commercial kit purchased from 
BioVision. HUVECs were grown in 75 cm2 flasks for 3 d. Each day the media was 
changed and given a dose of fluvastatin, simvastatin, or nothing (control). On the fourth 
day, the cells were collected by trypsinization as described above. Cell numbers were 
and 3x106 cells were extracted in 600 μl chloroform:isopropanol:Triton X-100 (7:11:0.1) 
and homogenized in a glass microhomogenizer. The extracts were then transferred to 1.7 
ml eppendorf tubes and spun at 20,000 rpm for 10 min. Three drops of distilled water 
were added after centrifugation to aid in layer separation. 150 μl of the lower phase was 
removed and transferred to a fresh eppendorf tube. The solvent was evaporated under a 
steady nitrogen stream and the lipid residue was dissolved in 600 μl Cholesterol 
Reaction Buffer by vortexing for 5 min. Cholesterol standards and reaction mix were 
prepared as written in the instruction manual. 50 μl of sample or standard and 50 μl of 
reaction mix were added to wells in a 96-well plate, covered in foil, and incubated for 1 
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h at 37°C while protecting from light. The plate was then analyzed using a 
spectrophotometer at 570 nm in a microplate reader.  
 
Protein analysis 
Extracts were collected by dissolving 2 gels from a 96-well plate in 150 μl of RIPA 
Detergent (for P-Erk 1/2) or directly into sample buffer (SB) (for P-Paxillin and P-Akt). 
Extracts were collected at incubation of the invasion experiment, 1 h after incubation, 
and 2 h after incubation. Gels were heated to 100°C and spun at 14000 rpm. The 
supernatant was collected and loaded onto 10 or 12% agarose gels. Proteins were 
separated using electrophoresis at 400 mA and 175 V for 1 h. Afterwards, the proteins 
were transferred to PVDF paper at 450 mA and 175 V for 1.5 h. After transfer, the 
PVDF membrane was washed with Tween-20 Saline prior to blocking with 5% milk 
solution for 1 h. After rinsing for 15 min with Tween-20 Saline, membranes were probed 
with primary antibody specific for the target protein by adding primary antibody in 5 ml 
of 5% BSA blocking solution and refrigerated with gentle shaking overnight. After 
washing 15 min with Tween-20 Saline, the signal was amplified by probing with an 
HRP-bound secondary antibody specific to the primary antibody strain in 10 ml of 5% 
milk solution for 1 h. Membrane was developed using chemiluminescence (ECL) after 
rinsing 15 min with Tween-20 Saline prior to adding 2ml of a 1:1 solution of luminal 
substrate and peroxidase. The membrane and ECL substrate reacted for 5 min prior to 
developing. HRP reaction levels were analyzed by exposing the membrane paper with 
radiological film (Denville Scientific) prior to developing using a kodak film processor.  
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Equal sample amounts were confirmed by a loading control. 25 ml of stripping buffer 
with ME were added to membranes and heated in a water bath at 50oC for 20 min. 
Membranes were then washed with Tween-20 Saline until no ME was detectable. 
Membranes were blocked in 5% milk solution for 1 h prior to probing with G3PDH 
mouse antibody in 5% BSA for 1 h. The remainder of the protocol was repeated as 
described above. 
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CHAPTER III 
RESULTS 
 
Statin therapy reduces cellular cholesterol levels 
When treated with simvastatin (10 nM), fluvastatin (160 nM), or vehicle (control) once a 
day for 3 days, the endothelial cells produced 12-17% less total cholesterol (free and 
esterified cholesterol) than the control cells, indicating statin treatment reduced 
cholesterol in ECs and demonstrating that treatment was successful. (Fig. 4) Fluvastatin 
was slightly more effective at reducing cholesterol levels than simvastatin. 
 
Fig. 4. Quantification of total cholesterol levels following statin treatment.72 h statin 
treatment significantly reduced total cholesterol levels in endothelial cells (n=1). The 
average absorbance indicate cholesterol levels in the control was 2.28 μg/well, while the 
average cholesterol levels in simvastatin and fluvastatin were 1.95 and 1.79 μg/well, 
respectively, when extrapolated from a standard curve (not shown). Error bars indicate 
the standard deviation. P-values determined relative to control. (* indicates a p-value 
<0.05, ** indicates a p-value<0.02). 
* **
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Statin treatment inhibits endothelial invasion  
In the collagen matrix, statin treatment reduced endothelial invasion by approximately 
20-30% (Fig. 5). Treating the cells with statins prior to invasion at lower doses did not 
differ significantly with treatment at higher doses. Earlier experiments involved pre-
treating the cells with statin 24 or 72 h prior to invasion, but the same results were 
obtained with treating the cells 20 min prior to invasion (not shown). 
  
Fig 5. Inhibition of endothelial invasion with statin treatment. Treatment with statin 
significantly decreased the average number of invading endothelial cells (n=3). A lower 
dose of simvastatin (1 nM) and fluvastatin (50 nM) yielded the same general result as a 
higher dose (10 nM and 160 nM). Error bars indicate the standard deviation. P-values 
determined relative to control. (*indicates a p-value <0.05, ** indicates a p-value <0.02). 
 
 
** ** ** *
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Protein analysis 
To explain why statins decrease invasion, we performed western blots with samples 
taken from invasion assays treated with vehicle (φ), fluvastatin (F), or simvastatin 
(S).The analysis of protein activation by SDS-PAGE indicated that there was no change 
in the phosphorylation or synthesis of Erk 1/2 (Fig. 6). Another term for Erk 1/2 are 
Mitogen-Activated Protein Kinase (MAPK) p42&p44. These numbers correspond to 
their molecular weight in kDa, which explains two bands on each side of the 43 kDa 
marker. A loading control was performed to verify the results; it is not known why there 
is only trace amounts of G3PDH in the 2 h fluvastatin sample.  
 
We also performed experiments to determine whether altered levels of P-Akt and P-
Paxillin might explain a decrease in invasion induced by simvastatin and fluvastatin. 
Conclusive data for Akt (Fig. 7) and Paxillin (Fig. 8) were note obtained. Light bands 
appeared corresponding to 60 and 68 kDa, respectively. A loading control performed on 
P-Akt verified that the lanes and extracts did contain cellular proteins and that the 
detection of protein on the blots was possible, therefore we must conclude that the 
antibodies used to prove for P-Akt and P-Paxillin bands were not functional in these 
experiments. P-Akt and P-Paxillin are known and crucial signaling proteins in the 
invasion process, usually highly expressed and maximized within the first 3 h.  
(unpublished data, Bayless laboratory) 
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Fig 6. Protein analysis of (A) P-Erk 1/2 & (B) loading control (n=3). φ indicates the 
control, F indicates fluvastatin therapy, and S indicates simvastatin therapy. Extracts 
were removed at 0, 1, and 2 hours of invasion. Primary antibody was diluted 1:1000, 
secondary antibody was diluted 1:5000. MAP-K activation reaches a maximum around 1 
h. The two bands correspond to two P-MAPK proteins with molecular weights 42 and 44 
kDa.  
 
 
  
 
 
 
Fig 7. Protein analysis of P-Akt (A) & loading control (B) (n>3). φ indicates the control, 
FS indicates fluvastatin therapy, and SS indicates simvastatin therapy. Primary antibody 
was diluted 1:1000, secondary antibody was diluted 1:5000.Although the bands are light, 
P-Akt appears highest in the control after 1 h. 
B 
A 
B 
A 
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Fig 8. Protein analysis of P-Paxillin (n=1). φ indicates the control, F indicates fluvastatin 
therapy, and S indicates simvastatin therapy. Primary antibody was diluted 1:2000, 
secondary antibody was diluted 1:3500. The strongest bands appear at 1 h and there 
appears to be no noticeable difference in P-Paxillin expression.  
  15 
CHAPTER IV 
SUMMARY AND DISCUSSION 
 
Summary 
Statin therapy significantly reduced total cholesterol levels in endothelial cells and 
inhibited endothelial invasion in a three-dimensional collagen matrix. While convincing 
data was not obtained for Akt and Paxillin activation, we discerned that these changes 
are not due to signaling changes in phsphorylated levels of Erk 1/2 during invasion. 
 
Discussion 
Three signals can stimulate endothelial invasion: a lipid signal, growth factors, and 
contact feedback. Erk 1/2 is activated downstream in the signaling cascade from the 
dimerization of tyrosine kinase receptors VEGFR and FGFR. [12]  Paxillin is activated 
downstream of integrins when cells come into contact with the extracellular matrix. [13-
14] Akt is activated downstream of the S1P receptor EDG1. [15]  
 
Integrins are transmembrane proteins with extra- and intra-cellular binding sites 
connected by a single membrane-spanning domain. [16] The α2β1 integrin is responsible 
for connecting the cell cytoskeleton to the membrane to a type I collagen extracellular 
matrix, and allowing the cell to attach to collagen. [17] They are also mediators of 
signaling processes in angiogenesis. [18] Tyrosine kinase receptors such as the VEGR 
and FGFR families are pairs of monomers with one transmembrane domain each. [19] 
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Binding of the ligand to the monomers causes the two subunits to dimerize, leading to 
trans-phosphorylation and activating a signaling pathway that phosphorylates Erk 1/2. 
Excessive Erk 1/2 activation has been implicated in poor cancer prognosis. [20] EDG1 is 
part of the EDG receptor families, unique in that it has higher affinity for S1P than 
LPA.[21-22] The EDG1 receptor has seven transmembrane domains. [23-24]  
 
We hypothesize that the lower cholesterol levels due to statin therapy cause less 
incorporation of cholesterol in the membrane, decreasing membrane fluidity and altering 
the conformation of receptors embedded in the membrane. We suggest that alterations in 
the membrane due to lower cholesterol would have the most profound effects on 
arrangement of the seven EDG1 domains, changing conformation of the receptor and 
decreasing its affinity for S1P. This would translate to a decrease in Akt phosphorylation 
and inhibition of endothelial invasion. Further work will be necessary to demonstrate 
this convincingly. 
 
Other studies have shown that integrins mediate tumor growth [25] and inhibiting 
angiogenic growth factors retards tumor growth in vivo. [26] Our method provides 
evidence that cholesterol-lowering statin therapy inhibits endothelial invasion, a crucial 
step in angiogenesis. The link between angiogenesis and tumor growth may help explain 
the cause of secondary protective effects witnessed with statin therapy. 
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